SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N
Combined Hypofractionated Stereotactic Body Radiotherapy With Immunomodulating Systemic Therapy for Inoperable Recurrent Head and Neck Cancer: Detection of the Maximum Tolerated Dose.
Sponsor: University Hospital, Ghent
Terminated
Poor recrual.
Other terminated trials from University Hospital, Ghent
Listed as NCT03402737, this NA trial focuses on Head and Neck Neoplasm and remains terminated or withdrawn. Sponsored by University Hospital, Ghent, it has been updated 7 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Mar 2021 — Jul 2024 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Jan 2021 — Mar 2021 [monthly]
Recruiting NA
-
Sep 2018 — Jan 2021 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Recruiting NA
-
Feb 2018 — Jun 2018 [monthly]
Recruiting NA
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Ghent
For direct contact, visit the study record on ClinicalTrials.gov .